Cue Biopharma (CUE) Cash & Current Investments (2017 - 2025)

Cue Biopharma has reported Cash & Current Investments for 9 years, with the latest figure at $27.7 million in Q4 2025.

• Quarterly Cash & Current Investments rose 21.84% year-over-year to $27.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.7 million (up 21.84% YoY) and the FY2025 annual result came in at $27.7 million, up 21.84% from the prior year.
• Cash & Current Investments advanced to $27.7 million in Q4 2025 per CUE's latest filing, from $12.9 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $76.3 million in Q4 2022 and troughed at $12.9 million in Q3 2025.
• A 5-year average of $48.2 million and a median of $53.4 million in 2021 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2021 and 2025: Cash & Current Investments soared 50.33% in 2021, then slumped 65.76% in 2025.
• Over 5 years, Cash & Current Investments stood at $52.2 million in 2021, then jumped by 46.12% to $76.3 million in 2022, then tumbled by 48.37% to $39.4 million in 2023, then slumped by 42.29% to $22.7 million in 2024, then increased by 21.84% to $27.7 million in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $27.7 million, $12.9 million, and $28.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.